Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients
Rebeca Lozano, David Lorente, Isabel M. Aragón, Nuria Romero-Laorden, Paz Nombela, Joaquı́n Mateo, Alison Reid, Ylenia Cendón, Diletta Bianchini, Casilda Llácer, Shahneen Sandhu, Adam Sharp, Pasquale Rescigno, Teresa Garcés, M.I. Pacheco, Penelope Flohr, Christophe Massard, Pedro P. López‐Casas, Elena Castro, Johann S. de Bono, David Olmos (2021). Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients. , 13(10), DOI: https://doi.org/10.3390/cancers13102334.
